TNF-α is another key regulator of inflammatory response, and preclinical studies suggest that it may act as a negative biomarker for ICI treatment through upregulation of PD-L1 on tumor cells and T cells [176] as confirmed by a small study on melanoma patients treated with nivolumab [177]. This evidence concerns the gene CD274 and neoplasm.